Relevant bibliographies by topics / Ferric ascorbate

Contents

  1. Journal articles
  2. Book chapters
  3. Conference papers

Academic literature on the topic 'Ferric ascorbate'

Author: Grafiati
Published: 7 June 2025
Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Ferric ascorbate.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Ferric ascorbate"

1

Divya, Sri Keerthika B. Priyanka B. P. Harith Mahesh Gomasa Dr. Swathi Boddupally*. "Study On Efficacy and Compliance of Oral Supplements with Ferric Pyrophosphate and Ferrous Ascorbate in Iron Deficiency Anaemia During Pregnancy." International Journal of Pharmaceutical Sciences 3, no. 5 (2025): 1080–86. https://doi.org/10.5281/zenodo.15354355.

Full text
Abstract:
Background: Iron deficiency anaemia in pregnancy is a nutritional disorder characterized by insufficient iron levels, leading to reduced haemoglobin production. This condition poses significant risks to both maternal and fatal health including increased chances of preterm birth, low birth, weight and maternal morbidity. It often results from inadequate dietary intake, poor iron absorption, or increased iron requirements during pregnancy. Early diagnosis and appropriate management through iron supplementation and dietary adjustments are crucial to mitigate adverse outcomes and promote healthy p
APA, Harvard, Vancouver, ISO, and other styles
2

Tamilselvan, T., Nissy Nelson Shanet, Ann Thomas Senorita, KM Shabla, and Sathyan Sneha. "Assessment of Efficacy and Cost-Effectiveness of Oral and IV Iron Therapy in Chronic Kidney Disease." Journal of Drug Delivery and Therapeutics 13, no. 11 (2023): 107–10. http://dx.doi.org/10.22270/jddt.v13i11.6306.

Full text
Abstract:
Introduction: Long-term iron therapy for anemia in chronic kidney disease patients is creating an economic burden and discontinuation of the treatment. Objective: The purpose of this study was to assess the cost-effectiveness and efficacy of oral and intravenous iron therapy and iron therapy. Methods: the patients were distributed into group 1 and group 2 and were administered with oral and intravenous iron therapy respectively. Baseline hemoglobin and packed cell volume were recorded and subsequently monitored in the next follow-up visit to assess the efficacy of the iron therapy. Results: Am
APA, Harvard, Vancouver, ISO, and other styles
3

Petrarulo, M., M. Marangella, O. Bianco, A. Marchesini, and F. Linari. "Preventing ascorbate interference in ion-chromatographic determinations of urinary oxalate: four methods compared." Clinical Chemistry 36, no. 9 (1990): 1642–45. http://dx.doi.org/10.1093/clinchem/36.9.1642.

Full text
Abstract:
Abstract In an attempt to decrease ascorbate interference on the ion-chromatographic determination of urinary oxalate, we compared the effectiveness of four different methods for ascorbate elimination by analyzing a representative urine pool supplemented with successive ascorbate additions. Two of the methods--treatment with ferric ions or boric acid--have been described elsewhere; treatments with nitrites or ascorbate oxidase (EC 1.10.3.3) are investigated here as possible alternatives. Consideration of the main features, advantages, and drawbacks of the four procedures leads us to conclude t
APA, Harvard, Vancouver, ISO, and other styles
4

McKie, Andrew T. "The role of Dcytb in iron metabolism: an update." Biochemical Society Transactions 36, no. 6 (2008): 1239–41. http://dx.doi.org/10.1042/bst0361239.

Full text
Abstract:
Dcytb (duodenal cytochrome b) is an iron-regulated ferric reductase highly expressed in duodenal enterocytes. Its location and strong regulation by iron has indicated it plays an important role in iron absorption. Expression of Dcytb in cells (Caco-2 and MDCK) was found to increase both ferric reductase activity and stimulate uptake of 59Fe. An additional increase in cupric reductase activity was found in MDCK (Madin–Darby canine kidney) cells expressing Dcytb. Expression and purification of Dcytb in insect cells reveals that Dcytb is a di-haem protein and that the haems are reducible by ascor
APA, Harvard, Vancouver, ISO, and other styles
5

Inamdar, Kalpana V., Keddy G. Raghavan, and Dinkar S. Pradhan. "Five treatment procedures evaluated for the elimination of ascorbate interference in the enzymatic determination of urinary oxalate." Clinical Chemistry 37, no. 6 (1991): 864–68. http://dx.doi.org/10.1093/clinchem/37.6.864.

Full text
Abstract:
Abstract We evaluated the efficacies of five treatment procedures for eliminating ascorbate interference in the enzymatic determination of urinary oxalate. Aliquots of urine samples, containing different amounts of added ascorbate and oxalate, were individually subjected to ferric chloride, sodium nitrite, sodium periodate, charcoal, or ascorbate oxidase treatment to eliminate ascorbate interference. Oxalate contents of the urine samples were then determined by a banana oxalate oxidase-horseradish peroxidase-linked assay with 3-methyl-2-benzothiazolinone hydrazone and 3-(dimethylamino)benzoic
APA, Harvard, Vancouver, ISO, and other styles
6

Kulkarni, Prashant, and Sasikumar Menon. "A randomized open-label study to compare iron content in the blood of healthy subjects treated with Tasiron tablets containing ferric di-phosphate as compared to tablets containing ferrous ascorbate." International Journal of Advances in Medicine 10, no. 12 (2023): 836–39. http://dx.doi.org/10.18203/2349-3933.ijam20233567.

Full text
Abstract:
Iron deficiency anemia (IDA) frequently affects reproductive-age women, pregnant women, and children of growing age, particularly in developing countries like India. Traditional oral iron supplementation has various side effects, and therefore, liposomal technology has been introduced. This study compared serum iron levels in healthy adult female subjects treated with Tasiron tablets containing 30 mg (elemental iron) of micronized liposomal ferric di-phosphate, with those administered with tablets containing 100 mg (elemental iron) of ferrous ascorbate, over 15 days. The test group (n=7) recei
APA, Harvard, Vancouver, ISO, and other styles
7

Atanasova, Bisera D., Andy CY Li, Ingvar Bjarnason, Kamen N. Tzatchev, and Robert J. Simpson. "Duodenal ascorbate and ferric reductase in human iron deficiency." American Journal of Clinical Nutrition 81, no. 1 (2005): 130–33. http://dx.doi.org/10.1093/ajcn/81.1.130.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lane, Darius J. R., Stephen R. Robinson, Hania Czerwinska, Glenda M. Bishop, and Alfons Lawen. "Two routes of iron accumulation in astrocytes: ascorbate-dependent ferrous iron uptake via the divalent metal transporter (DMT1) plus an independent route for ferric iron." Biochemical Journal 432, no. 1 (2010): 123–32. http://dx.doi.org/10.1042/bj20101317.

Full text
Abstract:
Astrocytes are central to iron and ascorbate homoeostasis within the brain. Although NTBI (non-transferrin-bound iron) may be a major form of iron imported by astrocytes in vivo, the mechanisms responsible remain unclear. The present study examines NTBI uptake by cultured astrocytes and the involvement of ascorbate and DMT1 (divalent metal transporter 1). We demonstrate that iron accumulation by ascorbate-deficient astrocytes is insensitive to both membrane-impermeant Fe(II) chelators and to the addition of the ferroxidase caeruloplasmin. However, when astrocytes are ascorbate-replete, as occu
APA, Harvard, Vancouver, ISO, and other styles
9

Piotrowsky, Alban, Markus Burkard, Katharina Hammerschmidt, et al. "Analysis of High-Dose Ascorbate-Induced Cytotoxicity in Human Glioblastoma Cells and the Role of Dehydroascorbic Acid and Iron." Antioxidants 13, no. 9 (2024): 1095. http://dx.doi.org/10.3390/antiox13091095.

Full text
Abstract:
Several studies have demonstrated, both in vitro and in animal models, the anti-tumor efficacy of high-dose ascorbate treatment against a variety of tumor entities, including glioblastoma, the most common and aggressive primary malignant brain tumor. The aim of this study was to investigate the effects of high-dose ascorbate as well as dehydroascorbic acid on human glioblastoma cell lines and to evaluate different treatment conditions for the combined administration of ascorbate with magnesium (Mg2+) and iron (Fe3+). Intracellular levels of reactive oxygen species and the induction of cell dea
APA, Harvard, Vancouver, ISO, and other styles
10

Amin, Shabana, Shazia Nisar, and S. Arif Kazmi. "Stopped-Flow Kinetic Study of Reduction of Ferric Maltol Complex by Ascorbate." JOURNAL OF ADVANCES IN CHEMISTRY 12, no. 4 (2016): 4338–41. http://dx.doi.org/10.24297/jac.v12i4.2174.

Full text
Abstract:
Stopped-flow kinetic investigation of reduction of Fe(III)-maltol complex is reported. The rates are dependent on pH in a complex way. On one hand at low pH there is a predominance of Fe(III)(maltol)2 which is easier to reduce compared to Fe(III) (maltol)3 which is more resistant to reduction. On the other hand ascorbate is a stronger reducing agent at higher pH. The rates are also found to be inversely dependent on the concentration of free ligand. These observations are explained by the following rate law:Rate = ((k0 +k1[H+])k2 [Asc-]/ (k-1[HMal] + k2[Asc-])) + k3 [Asc-] ) [FeIII(Mal)3] Here
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Ferric ascorbate"

1

Gutteridge, J. M. C. "Speciation of ferrous ions in biological fluids." In Experimental protocols for reactive oxygen and nitrogen species. Oxford University PressOxford, 2000. http://dx.doi.org/10.1093/oso/9780198506683.003.0052.

Full text
Abstract:
Abstract When plasma transferrin is fully iron-loaded and LMrFe is present (see Chapter 51) such iron would be kept in the ferric state by the ferroxidase activity of caeruloplasmin (see Chapter 31). If, however, ascorbate concentrations are high and caeruloplasmin levels low, plasma ferroxidase activity will be inhibited and LMrFe will be converted to the ferrous form.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Ferric ascorbate"

1

Krstić, Danijela Z., Jelena J. Žakula, Lela B. Korićanac, Nada Savić, Tatjana Parac-Vogt, and Mirjana B. Čolović. "ANTI-HUMAN MELANOMA ACTIVITY OF Fe(III)-CONTAINING WELLS- DAWSON POLYANION: THE EFFECT OF ASCORBATE." In 17th International Conference on Fundamental and Applied Aspects of Physical Chemistry. Society of Physical Chemists of Serbia, 2024. https://doi.org/10.46793/phys.chem24ii.607k.

Full text
Abstract:
This study aimed to investigate the simultaneous effect of Fe(III)-substituted monolacunary Wells-Dawson polyoxometalate (Fe-WD), K7[FeIII(α2-P2W17O61)(H2O)] and L(+)-ascorbic acid sodium salt (ascorbate) on cell viability of human melanoma A375 cells. A375 cells were exposed in vitro to Fe-WD (0.001 – 1 mM), ascorbate (0.040 – 40 mM), and Fe-WD/ascorbate mixtures (concentration ratio 1:40) for 24, 48, and 72 h. Fe-WD and ascorbate inhibited cell viability in a concentration-dependent manner for three treatment durations. Obtained EC50 values were 1, 0.58, and 0.52 mM (for 24-, 48-, and 72-hou
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Ferric ascorbate' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography